96 related articles for article (PubMed ID: 8713686)
21. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally AV
Int J Cancer; 1994 May; 57(4):574-80. PubMed ID: 7910153
[TBL] [Abstract][Full Text] [Related]
22. CCK/gastrin antagonists--clinical perspectives.
Calam J
Acta Gastroenterol Belg; 1993; 56(3-4):251-6. PubMed ID: 8266765
[TBL] [Abstract][Full Text] [Related]
23. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.
Williams CS; Goldman AP; Sheng H; Morrow JD; DuBois RN
Neoplasia; 1999 Jun; 1(2):170-6. PubMed ID: 10933052
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model.
Akhter J; Chen X; Bowrey P; Bolton EJ; Morris DL
Dis Colon Rectum; 1997 Mar; 40(3):317-21. PubMed ID: 9118747
[TBL] [Abstract][Full Text] [Related]
25. Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation.
Hsu HH; Chen MC; Day CH; Lin YM; Li SY; Tu CC; Padma VV; Shih HN; Kuo WW; Huang CY
World J Gastroenterol; 2017 Feb; 23(7):1171-1179. PubMed ID: 28275297
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
Radulovic S; Miller G; Schally AV
Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative effect of a novel cholecystokinin-B/gastrin receptor antagonist, YM022.
Murayama T; Matsumori Y; Iwata N; Ito M; Taniguchi T; Chihara K; Matsui T
Jpn J Cancer Res; 1996 Jul; 87(7):743-50. PubMed ID: 8698625
[TBL] [Abstract][Full Text] [Related]
29. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
[TBL] [Abstract][Full Text] [Related]
30. Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B.
Bold RJ; Ishizuka J; Townsend CM; Thompson JC
Biochem Biophys Res Commun; 1994 Aug; 202(3):1222-6. PubMed ID: 8060296
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
32. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
[TBL] [Abstract][Full Text] [Related]
33. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
34. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer.
Robertson JF; Watson SA; Hardcastle JD
Int J Cancer; 1995 Sep; 63(1):69-75. PubMed ID: 7558455
[TBL] [Abstract][Full Text] [Related]
35. Flavone inhibition of tumor growth via apoptosis in vitro and in vivo.
Chen YC; Shen SC; Chow JM; Ko CH; Tseng SW
Int J Oncol; 2004 Sep; 25(3):661-70. PubMed ID: 15289867
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
37. The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.
Singh L; Field MJ; Vass CA; Hughes J; Woodruff GN
Br J Pharmacol; 1992 Jan; 105(1):8-10. PubMed ID: 1350747
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances the sensitivity to cisplatin.
Yu Y; Sun P; Sun LC; Liu GY; Chen GH; Shang LH; Wu HB; Hu J; Li Y; Mao YL; Sui GJ; Sun XW
Biochem Biophys Res Commun; 2006 Jan; 339(1):71-8. PubMed ID: 16297858
[TBL] [Abstract][Full Text] [Related]
39. 1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice.
Su Y; Vanderlaag K; Ireland C; Ortiz J; Grage H; Safe S; Frankel AE
Breast Cancer Res; 2007; 9(4):R56. PubMed ID: 17764562
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth.
Watson SA; Crosbee DM; Morris DL; Robertson JF; Makovec F; Rovati LC; Hardcastle JD
Br J Cancer; 1992 Jun; 65(6):879-83. PubMed ID: 1616859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
